Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1481-1500 of 2,251 trials

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine

Hemorrhoidal Disease: RAFAELO® Procedure with Pain Management

We are studying whether adding perianal infiltration during the RAFAELO® procedure helps reduce pain after treatment for hemorrhoids. This trial aims to improve comfort for patients undergoing this procedure.

Hemorrhoids>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Ginisortamab for Advanced Pancreatic Cancer

We are studying the safety and effectiveness of ginisortamab combined with standard treatments for metastatic pancreatic cancer. This trial will help us understand how well it works and its potential side effects.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesGastroenterologyOncology

Non-Small Cell Lung Cancer: 68GaNOTA-Anti-MMR Imaging Study

We are testing a new imaging agent to see how well it can identify certain immune cells in patients with non-small cell lung cancer. This may help improve imaging techniques for better diagnosis and treatment planning.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngologyPulmonology

Multiple Myeloma: Elranatamab Combination Therapy

We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.

Multiple Myeloma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Metycor Study for Autonomous Cortisol Secretion

We are testing a new treatment to see if it improves blood pressure, glucose levels, and overall health in patients with autonomous cortisol secretion. The study also looks at effects on weight, bone health, and quality of life.

Mild Autonomous Cortisol Secretion6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Yellow Fever Vaccination: Comparing Injection Methods

We are studying how different ways of giving the yellow fever vaccine affect the immune response in participants. This trial aims to find out which method may provide better protection and safety.

Yellow Fever3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Advanced Melanoma: Enfortumab Vedotin with Pembrolizumab

We are studying a combination of two treatments for patients with advanced melanoma who have been previously treated. The goal is to see if this combination is effective and safe for improving patient outcomes.

Metastatic MelanomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Solid Tumors: Long-Term Safety of Brigimadlin

We are studying the long-term effects of brigimadlin in people with solid tumors who have previously taken this medication. The goal is to understand how well they tolerate it and any side effects that may occur.

Solid TumoursEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

HER2+ Metastatic Colorectal Cancer: Tucatinib Combination Study

We are investigating whether a new treatment combining tucatinib, trastuzumab, and mFOLFOX6 can improve outcomes for patients with HER2+ metastatic colorectal cancer compared to standard care.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Clear Cell Renal Cell Carcinoma: PET Scan Comparison

We are comparing two different PET scans to see which one detects tumors better in patients with clear cell renal cell carcinoma. This study may help improve diagnosis for those suspected of having this type of cancer.

Metastatic Renal Cell Carcinoma≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Dent 2 Disease: Alpelisib Study

We are testing the medication alpelisib in patients with Dent 2 disease to see if it improves kidney function and is safe to use. This study will help us understand its potential benefits for kidney health.

Dent's DiseaseEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrologyUrology

Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

Malignant Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Spinal Muscular Atrophy: Nusinersen via ThecaFlex DRx System

We are studying how the body processes nusinersen when given through the ThecaFlex DRx system in adults and children with spinal muscular atrophy. This research aims to compare it to the standard delivery method.

Spinal Muscular Atrophy1-2 yearsSafety phase (I)No PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced NSCLC: NVL-655 Treatment Study

We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK MutationSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Headache Relief: Sphenopalatine Block for Subarachnoid Hemorrhage

We are studying whether a nerve block can help reduce headaches and the need for pain medication in patients with non-traumatic subarachnoid hemorrhage. This trial also looks at patient satisfaction and potential complications.

Subarachnoid Hemorrhage>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology